tebipenem has been researched along with Disease-Models--Animal* in 2 studies
2 other study(ies) available for tebipenem and Disease-Models--Animal
| Article | Year |
|---|---|
Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection.
The combination of the β-lactam tebipenem and the β-lactamase inhibitor avibactam shows potent bactericidal activity against Mycobacterium abscessus Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Lung; Mice; Microbial Sensitivity Tests; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous | 2023 |
Characterization of SPR994, an Orally Available Carbapenem, with Activity Comparable to Intravenously Administered Carbapenems.
Carbapenems are potent antibacterials with broad-spectrum activity. However, poor oral absorption generally confines this important drug class to in-hospital use by intravenous (IV) administration. The continued rise in drug resistant pathogens creates a need for alternative oral therapies with broad-spectrum activity. SPR994 is a novel formulation of the orally bioavailable pivoxil prodrug of SPR859 (tebipenem) and is being developed as the first oral carbapenem for treatment of complicated urinary tract infections (cUTIs) in adults. Herein, we describe characteristics beneficial to oral administration and compare the in vitro and in vivo activity of SPR859 or SPR994 with IV carbapenems. Topics: Administration, Intravenous; Administration, Oral; Adult; Animals; Anti-Bacterial Agents; Biological Availability; Carbapenems; Disease Models, Animal; Gastrointestinal Microbiome; Gram-Negative Bacteria; Gram-Positive Bacteria; Hospitalization; Humans; Male; Mice; Microbial Sensitivity Tests; Treatment Outcome; Urinary Tract Infections | 2018 |